<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777617</url>
  </required_header>
  <id_info>
    <org_study_id>202011048</org_study_id>
    <nct_id>NCT04777617</nct_id>
  </id_info>
  <brief_title>Allosure in Simultaneous Pancreas Kidney Transplant</brief_title>
  <official_title>Assessment of Donor Derived Cell-free DNA in Combined Kidney-pancreas Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CareDx</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will observe donor derived cell free DNA percentages (via the Allosure test) in&#xD;
      combined kidney-pancreas transplant recipients to establish both stable and dysfunctional&#xD;
      Allosure assay levels&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Simultaneous kidney-pancreas transplantation is the optimal treatment for select patients&#xD;
      with type 1 diabetes and kidney failure. Limited biomarkers are utilized to monitor the&#xD;
      health of the allografts. For kidney transplantation serum creatinine remains the most&#xD;
      commonly monitored biomarker; for the pancreas allograft blood glucose and serum amylase and&#xD;
      lipase are measured. However, these biomarkers are imprecise and non-specific for rejection.&#xD;
&#xD;
      In kidney transplantation cell free donor derived DNA at of value of &gt;1% has emerged as an&#xD;
      effective immune monitoring tool as a marker for renal allograft rejection and injury. Thus&#xD;
      far, a discriminatory donor derived cell free DNA value for a stable and rejecting allografts&#xD;
      has not been established for recipients of combined kidney-pancreas transplants.&#xD;
&#xD;
      Study aim will be to help establish a normal range of donor derived cell free DNA in stable&#xD;
      kidney-pancreas graft function in combined kidney pancreas transplant recipients while&#xD;
      determining changes in cell free DNA in kidney-pancreas recipients with biopsy proven&#xD;
      allograft rejection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DD-cfDNA level</measure>
    <time_frame>1 year</time_frame>
    <description>determine level of donor derived cell free DNA from SPK patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Kidney Pancreas Transplant</condition>
  <arm_group>
    <arm_group_label>WU/Barnes cohort</arm_group_label>
    <description>SPK patients in this group will be recruited from WU/Barnes Transplant center. A total of 25 from this cohort will be recruited and asked to provide a blood sample to test for donor derived cell free DNA 3 times over the course of the first year of transplant. In addition, if any biopsies or rejections occur, additional samples will be requested at the time of biopsy and for an additional two follow-ups at least one month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UT Southwestern cohort</arm_group_label>
    <description>SPK patients in this group will be recruited from WU/Barnes Transplant center. A total of 25 from this cohort will be recruited and asked to provide a blood sample to test for donor derived cell free DNA 3 times over the course of the first year of transplant. In addition, if any biopsies or rejections occur, additional samples will be requested at the time of biopsy and for an additional two follow-ups at least one month apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DD-cfDNA</intervention_name>
    <description>We are obtaining samples for donor derived cell free DNA in an observational manner. There is no intervention in this study</description>
    <arm_group_label>UT Southwestern cohort</arm_group_label>
    <arm_group_label>WU/Barnes cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This population will be SPK patients with stable Cr, lipase and amylase for at least 2&#xD;
        months post transplant and enrolled within the first year after transplant&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 years&#xD;
&#xD;
          -  Kidney-pancreas transplant recipients&#xD;
&#xD;
          -  Patient must have stable creatine, lipase, amylase for at least a two month span after&#xD;
             transplant OR patient must receive a biopsy within one year post transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of non-renal or pancreas transplanted organ&#xD;
&#xD;
          -  Patient is not enrolled within 1 year after transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Rowena Delos Santos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University in Saint Louis School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rowena Delos Santos</last_name>
    <phone>314-362-8351</phone>
    <email>delossantos@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Devin Wall</last_name>
    <phone>314-362-4109</phone>
    <email>devinwall@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rowena Delos Santos, MD</last_name>
      <phone>314-362-8351</phone>
      <email>delossantos@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Rowena Delos Santos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Malone</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, Matas AJ, Mehta S, Mannon RB, Sharfuddin A, Fischbach B, Narayanan M, Jordan SC, Cohen D, Weir MR, Hiller D, Prasad P, Woodward RN, Grskovic M, Sninsky JJ, Yee JP, Brennan DC; Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators. Cell-Free DNA and Active Rejection in Kidney Allografts. J Am Soc Nephrol. 2017 Jul;28(7):2221-2232. doi: 10.1681/ASN.2016091034. Epub 2017 Mar 9.</citation>
    <PMID>28280140</PMID>
  </reference>
  <reference>
    <citation>Grskovic M, Hiller DJ, Eubank LA, Sninsky JJ, Christopherson C, Collins JP, Thompson K, Song M, Wang YS, Ross D, Nelles MJ, Yee JP, Wilber JC, Crespo-Leiro MG, Scott SL, Woodward RN. Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients. J Mol Diagn. 2016 Nov;18(6):890-902. doi: 10.1016/j.jmoldx.2016.07.003. Epub 2016 Oct 7.</citation>
    <PMID>27727019</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney pancreas transplant</keyword>
  <keyword>Deceased donor cell free DNA</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

